Daniel Sumarriva: What a Heroic Journey to Bring Pathlight MRD to lluminate the Way for Cancer Patients
Daniel Sumarriva, Executive Medical Director at SAGA Diagnostics, shared SAGA Diagnostics’s post on LinkedIn:
“What a heroic journey to bring Pathlight MRD to illuminate the way for cancer patients! So proud of our SAGA team from the the Research And Development in Sweden to our commercial lab here in the USA.
Still wrapping my mind around this.. Claims cover our target intended use for consecutive testing for a period of 6 years – this is the longest recurrence monitoring timeline MolDX has granted any MRD company!”
Quoting SAGA Diagnostics’s post:
“Today, we are thrilled to share the news that Palmetto GBA’s Molecular Diagnostic Services Progam (MolDX) issued a positive coverage decision for the Pathlight MRD test.
Pathlight is covered for Medicare beneficiaries for recurrence monitoring in the surveillance setting for up to six years in patients with stage II-III breast cancer, including all subtypes: HR+/HER2-, HER2+ and TNBC.
Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer patients in the US.
Read the full press release here.”
More posts featuring Daniel Sumarriva.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023